2004;279:20858C20865. JNJ-26854165, used either alone or in combination with TKIs, represents a promising novel targeted approach to overcome TKI resistance and improve patient outcome in CML. studies have shown that induction of p53 through MDM2 inhibition by the small-molecules such as Nutlins and MI219 effectively induces p53-mediated apoptosis in most blast crisis CML cells, with … Continue reading 2004;279:20858C20865